CDT-OncoCore™
Essential Screening Services for Early Drug Evaluation Ideal for biotech startups and early-stage research, CDT-OncoCore™ provides quick and reliable results for compound efficacy testing using 3D culture models. What’s Included: 🕒 Turnaround: 5–10 days per sample*
CDT-OncoPlus™
Advanced Phenotypic and Mechanistic Profiling Perfect for customers interested in a deep understanding of MOA and efficacy. CDT-OncoPlus™ enhances your understanding of tumor response and drug impact with deeper biological analysis. What’s Included: 🕒 Turnaround: 10–12 days per sample*
CDT-OncoMax™
Comprehensive, Multi-Dimensional Testing Deliver the comprehensive report to support IND application CDT-OncoMax™ delivers high-resolution, immune-integrated profiling across multiple biological layers. What’s Included: 🕒 Turnaround: 10–12 days per sample*
CDT-OncoFlex™
Fully Tailored, High-Impact Testing Solutions When your project needs go beyond off-the-shelf services, CDT-OncoFlex™ is your solution. Collaborate with our scientific team to build a custom testing program using various state-of-the-art tools. Customizable Features Include: 🕒 Turnaround time: Varies based on selected features*
3D Models Are Reshaping Drug Development PrecliniX Is at the Forefront
A recent article in Drug Target Review highlights how 3D cell culture models are revolutionizing pre-clinical drug development by providing more accurate, human-relevant data earlier in the pipeline. These models better replicate human tissue complexity and immune interactions, offering a significant leap beyond traditional 2D cultures and animal models. At PrecliniX, we are advancing this […]
A New Era Begin FDA Plans to Phase Out Animal Testing Requirements
In a groundbreaking move, the FDA has announced plans to phase out animal testing requirements for monoclonal antibodies and other select drugs. This shift marks a historic step toward more humane, innovative, and human-relevant approaches in drug development. The updated strategy opens the door for modern testing platforms—like organ-on-a-chip systems, 3D tissue models, and advanced […]
Organ-on-a-Chip Market Set to Surpass $1.66 Billion by 2032
According to a recent report by Astute Analytica, the global Organ-on-a-Chip market is projected to reach USD 1,665.91million by 2032, growing at a CAGR of 29.9% from 2023 to 2032. This rapid growth reflects the increasing demand foradvanced preclinical testing tools closely mimicking human biology.The momentum behind Organ-on-a-Chip technologies underscores a global shift toward personalized […]